– USA, CA – CURE Pharmaceutical Holdings (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products, and drug delivery, today announced the appointment of Board member Rubén J. King-Shaw Jr as Chairman of its Board of Directors, succeeding William Yuan who is transitioning to Chairman Emeritus.
Rubén José King-Shaw Jr, a highly qualified and respected member of the Board brings with him three decades of executive leadership experience in the healthcare technology and private equity sectors.
The company also announced the addition of Dov Szapiro to its Board of Directors.
“We thank Mr. Yuan for his dedicated leadership of CURE’s Board of Directors and we are honored to have him stay with us as Chairman Emeritus and Key Advisor to the Board and executive team, as he leads the Company in its continued progress for dynamic international expansion and global revenue traction. As our Company continues to grow and evolve, so does our Board of Directors and we are confident in Mr. King-Shaw Jr.’s ability to lead our Board in continued success,” said CEO, Rob Davidson.
I “We are also honored to have Mr. Szapiro join us as one of the cannabis industry’s lead investors. Through his decades of experience as a founder and CEO leading companies from scaling up to exit, as well as an investor and board member, he has gained valuable knowledge of what it takes to drive a publicly-traded company to success and we look forward to working with him in our various business development initiatives, driving an accretive M&A strategy to execute our growth plans and further expand our presence in the wellness space, including the endocannabinoid research division.”
About Rubén José King-Shaw Jr
He recently served on the board of Atlanta-based Cotiviti Holdings, Inc. and currently serves on the board of US Retina of Denver, CO. Past board service consists of Lead Director of Athenahealth; Independent Living Systems, of Miami, FL; and WellCare Health Plans, Inc. of Tampa, FL. Mr. King-Shaw served on the Obama Administration’s Medicare Program Advisory and Oversight Committee and he was COO and Deputy Administrator of the Centers for Medicare and Medicaid Services during the administration of President George W. Bush, administering a federal budget of $600 billion. Mr. King-Shaw also served as Senior Advisor to the Secretary of the US Treasury.
He is currently serving as Chief Strategy Officer of Steward Health Care Systems, LLC, and has held C-suite positions with leading private companies including Neighborhood Health Partnership, Inc. and JMH Health Plan.
About Dov Szapiro
Mr. Szapiro brings more than 20 years of experience as a CEO, investor, advisor, and board member in companies across multiple industries and different growth phases. Currently, he serves as a Co-Founder, Managing Partner, and Principal of Entourage Effect Capital, one of the cannabis industry’s most highly regarded investment firms. Before Entourage Effect Capital, Mr. Szapiro co-founded AFS Acceptance LLC, where he served as President and CEO. As AFS’ CEO, Mr. Szapiro’s main responsibility was to provide the vision and strategic leadership for AFS to expand into 30 states. In 2015, Mr. Szapiro led the negotiations of a strategic sale to Credito Real SAB de CV, Mexico’s largest non-bank financial institution listed in the Mexican Stock Exchange. Before co-founding AFS, Mr. Szapiro was a Director of business development for GovWorks, Inc, an internet start-up in the e-government sector. Earlier in his career, Mr. Szapiro was an analyst for Bassini, Playfair + Associates, a $1.2 billion emerging markets private equity firm. Mr. Szapiro also serves as a Member of the Board of Directors of several companies including Conception Nurseries, a global leader focused on tissue culture micropropagation for the cannabis industry.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical is the pioneering developer of CUREform, a patented drug delivery platform that offers several unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF and cGMP-certified manufacturing facility enable it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
For more information: https://www.curepharmaceutical.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.